ADORA2A

Adenosine receptor A2a · P29274 · ADORA2A on Sugi Atlas →

469,236 patent compounds predicted against ADORA2A, 238,074 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL25861	0.75	11/20
SCHEMBL19841	0.69	11/20
SCHEMBL8273	0.59	11/20
SCHEMBL9120	0.59	11/20
Isobutylmethylxanthine (SCHEMBL50315)	0.78	10/20
SCHEMBL67131	0.74	10/20
SCHEMBL38913	0.70	10/20
SCHEMBL8565	0.58	10/20
SCHEMBL59949	0.72	9/20
SCHEMBL60158	0.70	9/20
SCHEMBL61922	0.53	9/20
3-Ethyladenine (SCHEMBL48200)	0.50	9/20
Theophylline Anhydrous (SCHEMBL4915)	0.96	8/20
Theophylline Anhydrous (SCHEMBL5037)	0.81	8/20
SCHEMBL31503	0.53	8/20
SCHEMBL48434	0.53	8/20
2-Methyladenosine (SCHEMBL41422)	0.74	7/20
2-Methyladenosine (SCHEMBL41423)	0.74	7/20
Fludarabine (SCHEMBL3510)	0.73	7/20
Fludarabine (SCHEMBL4105)	0.67	7/20

Clinical trials — most relevant to ADORA2A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI	PHASE4	RECRUITING
Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia	PHASE4	COMPLETED
Stress Testing and Cardiac Magnetic Resonance	PHASE4	COMPLETED
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)	PHASE4	COMPLETED
Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode	PHASE3	COMPLETED
Preventing Acute Kidney Injury (AKI) in Pediatric Patients	PHASE3	UNKNOWN
Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease	PHASE2/PHASE3	COMPLETED
Caffeine for Motor Manifestations of Parkinson's Disease	PHASE2	COMPLETED
Clonidine Versus Adenosine to Treat Neuropathic Pain	PHASE2	COMPLETED
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer	PHASE2	RECRUITING
KW-6002 to Treat Parkinson's Disease	PHASE2	COMPLETED
Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation	PHASE1	UNKNOWN
New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer	PHASE1	COMPLETED
Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444	PHASE1	COMPLETED
Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.	PHASE1	COMPLETED
Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System	EARLY_PHASE1	COMPLETED
Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration	EARLY_PHASE1	COMPLETED
Effects of Aminophylline on Renal Function and Urine Volume of AKI Patient	EARLY_PHASE1	UNKNOWN
Quantitative Assessment of BB-02 Therapy Effect on Cartilage Status in Patients Affected by Early Knee Osteoarthritis	nan	RECRUITING
Pilot Study on Caffeine Efficiency in ADCY5-related Dyskinesia	nan	COMPLETED
Motivational, Affective and Performance Effects of Caffeine Supplementation	nan	UNKNOWN
Sublingual Caffeine on Reducing Recovery Time and Postoperative Agitation in Elderly Patients Undergoing General Anesthesia	nan	RECRUITING
Genetic Causes of Panic Disorder	nan	COMPLETED
Adenosine and A2A Receptors in Human Brown Adipose Tissue	nan	COMPLETED
Poor Sleep and Inflammation in HIV-Infected Adults	nan	COMPLETED
Caffeine Efficacy in ADCY5-related Dyskinesia	nan	UNKNOWN
Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia	nan	COMPLETED
Polymorphisms, Caffeine and Sleep Disorders	nan	COMPLETED
Contribution of the Pharmacological Profile of the A2A Receptor to Adenosine in the Diagnosis of Myocardial Ischemia	nan	UNKNOWN
The Effect Of Coffee And Tea Drink On Gis Functions Healing Quality After Surgery in Patients Surgery	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ADORA2A binder may also engage these)

Protein	Name	Similarity
P11617	—	1.000	P11617 →
Q60613	—	1.000	Q60613 →
Q6TLI7	—	1.000	Q6TLI7 →
P46616	—	0.996	P46616 →
P30543	—	0.993	P30543 →
Q28997	—	0.980	Q28997 →
Q91178	—	0.979	Q91178 →
Q6W3F4	—	0.977	Q6W3F4 →
ADRA1A	Alpha-1A adrenergic receptor	0.976	landscape →
Q5IS72	—	0.976	Q5IS72 →
CNR2	Cannabinoid receptor 2	0.975	landscape →
Q60614	—	0.975	Q60614 →
Q1LZD0	—	0.974	Q1LZD0 →
P29276	—	0.974	P29276 →
ADORA2B	Adenosine receptor A2b	0.974	landscape →
P18130	—	0.973	P18130 →
P52703	—	0.973	P52703 →
P47752	—	0.973	P47752 →
Q9Z0L1	—	0.972	Q9Z0L1 →
B4XF06	—	0.972	B4XF06 →
P97292	—	0.972	P97292 →
DRD3	D(3) dopamine receptor	0.972	landscape →
P97718	—	0.972	P97718 →
P54833	—	0.972	P54833 →
Q864I2	—	0.971	Q864I2 →
Q6A155	—	0.971	Q6A155 →
P56489	—	0.971	P56489 →
P56448	—	0.971	P56448 →
Q91175	—	0.971	Q91175 →
Q9WU25	—	0.971	Q9WU25 →